Just watched SI presentation at the Share Cafe Webinar. My key takeaways:
aGvHD:
* Coming quarter refiling
* Second half of year potential approval
* Small sales force as 50% of transplant centres in US
* Substantial reimbursement revenues (launch towards end of year)
* Japan seeing 30 - 40% adoption in market after 3 years
* Potency assay to predict clinical survival - new data shows this
* Very confident - resubmit data short order - review process 2 to 6 months
* Reiterated 9:1 ODAC vote - extra data requested around potency assays
IBD
* Current drugs on market cost about $60,000/year
* Update next couple of months further results
* Initial results outstanding
CLBP
* Most valuable opportunity - multi billion projected annual sales opportunity
* Second half of year to start CLBP trial
Interestingly didn't expand of CHF - intriguing - make of it what you wish. My thoughts probably because in discussions with FDA.
Mentioned extremely happy to have Dr Krause on board - asset for navigating first and subsequent products.
SI looks confident.
Good luck all!
- Forums
- ASX - By Stock
- MSB
- MSB Trading 2022, The TurnAround
MSB Trading 2022, The TurnAround, page-721
-
- There are more pages in this discussion • 328 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
93.5¢ |
Change
0.020(2.19%) |
Mkt cap ! $1.067B |
Open | High | Low | Value | Volume |
92.0¢ | 94.5¢ | 92.0¢ | $1.622M | 1.742M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 64563 | 93.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
94.0¢ | 204239 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 64563 | 0.930 |
6 | 79973 | 0.925 |
13 | 254982 | 0.920 |
11 | 107275 | 0.915 |
4 | 115328 | 0.910 |
Price($) | Vol. | No. |
---|---|---|
0.940 | 204239 | 3 |
0.945 | 22942 | 2 |
0.950 | 91123 | 5 |
0.955 | 42425 | 1 |
0.960 | 61820 | 3 |
Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |